NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous ...

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

A groundbreaking study suggests that IBS might be more of a brain issue than a gut disorder. Researchers found that stress-induced IBS symptoms could be alleviated by drugs that regulate ...

Neuroscientists at the Sainsbury Wellcome Centre (SWC) at University College London have uncovered a neural mechanism in mice ...

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research.

The manufacturer of AV-101, an investigational, oral nonopioid, NMDA-targeting therapy to treat neuropathic pain, announced that it has received a U.S. patent for the treatment. AV-101 (4-Cl-KYN) is ...

New research reveals how CBD and THC interact with brain receptors, unlocking potential for safer cannabis-based treatments.

What if I’m doomed to live with this forever? Kendra Johnson thought as she looked in the mirror. The Spokane, Washington, ...

Research reveals that δ-receptor agonists like KNT-127 alleviate IBS symptoms by modulating gut-brain interactions and ...

Early dysfunction of the endothelial/blood-brain barrier (BBB) is involved in the pathogenesis of cerebral small vessel disease (SVD), which is a contributor to about 50% of dementias.

Researchers have identified how CBD interacts with cannabinoid receptors to mitigate the negative effects of THC, the psychoactive component of cannabis.

Naloxone is a fantastic tool in reducing opioid deaths, but gentler versions would be helpful for fighting overdose ...